1-Bromo-2-iodobenzene | CAS:583-55-1

We serve 1-Bromo-2-iodobenzene CAS:583-55-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1-Bromo-2-iodobenzene

Chemical Name:1-Bromo-2-iodobenzene
CAS.NO:583-55-1
Synonyms:1-Bromo-2-iodobenzene
ortho-bromoiodobenzene
1,2-bromo-iodobenzene
o-bromoiodobenzene
1-bromo-2-iodo-benzene
Benzene, 1-bromo-2-iodo-
Molecular Formula:C6H4BrI
Molecular Weight:282.90400
 
Physical and Chemical Properties:
Density:2.203
Melting point:9-10ºC
Boiling point:120-121ºC
Flash point:>230°F
Index of Refraction:1.661
 
Specification:
Appearance:Pale yellow to yellow liquid
Assay(GC):≥98.0%
Moisture:≤0.15%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 1-Bromo-2-iodobenzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzene, 1-bromo-2-iodo- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,o-bromoiodobenzene Use and application,1-bromo-2-iodo-benzene technical grade,usp/ep/jp grade.


Related News: The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route.(Chloromethyl)triethoxysilane manufacturer Among the APIs we produce, there is an API which passes through over ten kinds of intermediates in a process when it changes from being a raw material into an API.N-(2-Hydroxyethyl)-3,4-Methylenedioxyaniline Hydrochloride supplier Among the APIs we produce, there is an API which passes through over ten kinds of intermediates in a process when it changes from being a raw material into an API.2-Bromo-3-chloropyridine vendor Among the APIs we produce, there is an API which passes through over ten kinds of intermediates in a process when it changes from being a raw material into an API.From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend.